Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sionna Therapeutics, Inc. ( (SION) ) has provided an update.
On June 12, 2025, Sionna Therapeutics, Inc. held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s leadership and financial oversight. The meeting resulted in the election of three Class I directors, Joshua Resnick, Bruce Booth, and Lucian Iancovici, to serve until 2028, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (SION) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Sionna Therapeutics, Inc. stock, see the SION Stock Forecast page.
More about Sionna Therapeutics, Inc.
Average Trading Volume: 169,002
Current Market Cap: $761.6M
Learn more about SION stock on TipRanks’ Stock Analysis page.